In the randomized Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (intent to treat: 1,961 adults with overweight or obesity without T2D), once-weekly subcutaneous semaglutide 2.4 mg resulted in greater weight loss compared with placebo over a 68-week period (estimated treatment difference 12.4 percentage points, 95% confidence interval (CI) 13.4, 11.5
In many cases involving sperm abnormalities, the underlying cause is unknown, or is idiopathic
Abnormal results might mean a dose change, more frequent testing, additional tests, or stopping the drug
Several hormonal imbalances can make weight loss feel like an uphill battle: Insulin Resistance: Your pancreas produces insulin to help your cells absorb glucose (sugar) for energy
Some people may experience mild side effects such as stomach upset or allergic reactions
Ipamorelin is a promising peptide with potential benefits in muscle growth, recovery, and anti-ageing